person
as of 2026-07-01Matthew Leoni, MD, MBA
Matthew Leoni, MD
at a glance
Roles: Study Director, Author
KOL signal score 4
1 publications · 1 high-value
Cross-drug reach: 1 competitor drugs
Synthesized from structured facts only — each point cited above.
Profile
Affiliation
Cerevel Therapeutics, LLC
Roles
Study Director, Author
KOL signal
4
Publications
1 (1 high-value)
Trial investigator
no
Publishes on
1 drugs
Trials led
3
A Multiple Ascending Dose Trial of CVL-231 in Subjects With Schizophrenia
NCT04136873Phase 1Completed
Pharmacokinetics of CVL-231 Following Single Oral Administration of Modified- and Immediate-release Formulations in Fasted and Fed Healthy Participants
NCT05106309Phase 1Completed
PET Trial to Evaluate Target Occupancy of CVL-231 on Brain Receptors Following Oral Dosing
NCT04787302Phase 1Completed
Publications & congress
1
Emraclidine, a novel positive allosteric modulator of cholinergic M4 receptors, for the treatment of schizophrenia: a two-part, randomised, double-blind, placebo-controlled, phase 1b trial.
Lancet (London, England) · 2022 · high-value
Facts & assertions
0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
publishes on
drug
STUDY_DIRECTOR